ClinicalTrials.gg
CompletedNCT03883113Updated Mar 18, 2021Results posted

Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model

A Phase 2 interventional study of MVA-NP+M1 and Saline in Influenza, sponsored by Barinthus Biotherapeutics. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-18.

Sponsored by Barinthus Biotherapeutics · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
145
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 106 studies in Influenza, Human with a site in Belgium — 4 open to participants now, 5 under way, 2 of them phase 3. Influenza, Human · Belgium.

Enrollment
61st of 97
145 · median 243
Started
2019
with 5 others
Phase 2
33 of 106
none open now
Registered
85th of 106
by date

Among the 106 studies in Influenza, Human with a site in Belgium, this one is the 61st largest by enrollment of the 97 interventional ones that give a count, is one of 6 that started in 2019, is one of 33 in phase 2, and was the 85th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

4 of the 106 studies in Influenza, Human with a site in Belgium are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Influenza, Human with a site in Belgium, or all of them as a file.
02

Study summary

A Phase 2, single center, randomized, double blind study evaluating the safety, efficacy, and immunogenicity of MVA NP+M1 in the H3N2 human influenza challenge model; on healthy adult volunteers.

Read the detailed description

The study consists of an outpatient vaccination phase (155 participants), and at least 2 months later an inpatient challenge phase (134 participants). Participants are randomized 93:62 to receive either MVA-NP+M1 or Placebo. Up to 20 participants will be challenged over several 3-week blocks, and the remainder at the final 3-week block for a total of 80 MVA-NP+M1 and 54 Placebo recipients challenged.

03

Conditions studied

  • Influenza

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Healthy males and females aged ≥18 and ≤55 years of age at the point of enrolment.
  • Non-smokers or those who stopped smoking ≥ 3 months prior to screening 1 visit.
  • Willingness to remain in isolation for the duration of the study.
  • A female participant is eligible for this study if she is not pregnant or breast feeding and 1 of the following:

    1. Of non- (i.e., women who have had a hysterectomy or tubal ligation or are , as defined by no menses in greater than or equal to 1 year).
    2. Of childbearing potential but has been and agrees to continue practicing highly effective or abstinence (if this is the preferred and usual lifestyle of the participant) from 6 months prior to vaccination to 6 months after administration of the influenza challenge virus. Highly effective methods of contraception include 1 or more of the following:

    i. male partner who is sterile (vasectomised) prior to the female participants entry into the study and is the sole sexual partner for the female participant; ii. hormonal (oral, intravaginal, transdermal, implantable or injectable); iii. an intrauterine hormone-releasing system (IUS); iv. an intrauterine device (IUD) with a documented failure rate of \< 1%; v. bilateral tubal occlusion.

  • Pre-challenge serum microneutralization test (MNT) against A/Belgium/4217/2015 (H3N2) challenge strain \< 20.

Exclusion Criteria:

  • \< 19 and > 32.
  • Presence of any significant acute or chronic, uncontrolled medical (or psychiatric) illness including a history of chronic respiratory illness.
  • History of seasonal hay fever or a seasonal allergic rhinitis (SAR), including the use of symptomatic prescription only medication and non-prescription medication.
  • History or evidence of disease or known immunodeficiency of any cause - with the exception of atopic dermatitis/eczema and atopic rhinitis.
  • Any history of anaphylaxis in reaction to vaccination or history of allergic reactions likely to be exacerbated by any component of the vaccine.
  • History of lung disease (Asthma, ).
  • Current smokers or those who stopped smoking \< 3months prior to screening 1 visit.
  • Positive diagnostic tests for , or indicating active infection.
  • Evidence of drug abuse or a positive urine drug screen or alcohol breath test.
  • Chronic use of any medication or other product (prescription or over-the-counter), for symptoms of rhinitis or nasal congestion or for any chronic nasopharyngeal complaint, or chronic use of any intranasal medication for any indication that has not ceased within 30 days prior to screening 1.
  • Receipt of any drug within 3 months prior to vaccination, or prior participation in a clinical trial of any influenza vaccine, or any investigational vaccine or experimental influenza viral challenge delivered directly to the respiratory tract within 1 year prior to challenge.
  • Receipt of the 2018/2019 seasonal flu vaccine.
  • Receipt of any within the 4 weeks prior to vaccination.
  • Any laboratory test which is abnormal and which is deemed by the Investigator(s) to be clinically significant.
  • Receipt of any systemic chemotherapy agent at any time.
  • Physician reported influenza or a syndrome consistent with influenza (as judged by the investigator) in the previous 6 months.
  • Known allergy to treatments for influenza (including but not limited to oseltamivir).
  • History of frequent epistaxis (nose bleeds).
  • Any nasal or sinus surgery within 6 months of Viral Challenge or any significant abnormality, either of which results in alteration of the anatomy of the nose or nasopharynx (including significant nasal polyps).
  • Volunteers with household contacts who are at risk for serious or severe complications of influenza disease including, but not limited to: persons ≥ 65 years; presence of significant chronic cardiopulmonary, metabolic, renal, or neurological conditions; due to any condition or therapies; BMI >40.
  • Participants that are an employee or family member of the Investigator or study site personnel may not be enrolled.
  • Any other finding that, in the opinion of the Investigator, deems the participant unsuitable for the study.

EXCLUSION (CHALLENGE PERIOD ONLY)

  • Abnormal spirometry assessed to be clinically significant.
  • Known close contact with anyone known to have influenza in the past 7 days at the time of quarantine.
  • Influenza-like illness (ILI) symptoms as assessed at the admission to clinic on Day -2 prior to challenge.
  • Presence of fever, defined as participant presenting with a temperature reading of > 38.0°C on admission to quarantine.
  • Qualitative Polymerase chain reaction (PCR) results positive for viral infection. However, participants may be included into later challenge cohort.
  • Acute use of any medication or other product, prescription or over-the-counter, for symptoms of rhinitis or nasal congestion within 7 days prior to challenge. This includes any oral or beta agonist containing nasal spray.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
145 participants (actual)

Study arms

  • Experimental
    MVA-NP+M1 & H3N2 Challenge Virus

    Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10\^8 pfu.); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10\^6 TCID50/ml)

    Biological: MVA-NP+M1 · Biological: H3N2 (A/Belgium/2417/2015)

  • Placebo comparator
    Saline Placebo & H3N2 Challenge Virus

    Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10\^6 TCID50/ml)

    Biological: Saline · Biological: H3N2 (A/Belgium/2417/2015)

Interventions

06

What researchers measure

Primary outcomes

  1. Degree of Nasopharyngeal Viral Shedding as Determined by Quantitative Polymerase Chain Reaction qPCR

    Measure of nasopharyngeal viral shedding during challenge; recorded as viral area under curve (vAUC) as determined by quantitative real time polymerase chain reaction (qRT-PCR). vAUC is calculated by plotting the log viral particles number/ml for each time point against time and is using the trapezoidal rule.

    Time frame: Throughout 9 days (Day2, Day3, Day4, Day5, Day6, Day7, Day8, Day9, Day10) after viral Inoculation (Day1) of the challenge phase. Nasal swabs taken twice a day (b.i.d) at least 8 hours apart.

Secondary outcomes

  1. Number and Percentage of Virologically Confirmed Influenza-Like Illness

    Incidence (frequency tabulation) of laboratory-confirmed influenza-like illness compared between vaccine and placebo arms Virologically confirmed influenza-like illness (ILI) is defined as having respiratory or flu-like symptom occurring on two consecutive days, along with a positive qPCR or qCulture result.

    Time frame: 9 days from day 2 to day 10

  2. Percentage of Participants With Attack Rate of Challenge Agent (qRT-PCR)

    The attack rate is defined as the percentage of inoculated participants with at least two consecutive positive swabs as determined by qRT-PCR within the timespan of two consecutive days

    Time frame: 9 days from day 2 to day 10

  3. Percentage of Participants With Quantitative Culture Attack Rate of Challenge Agent (qCulture)

    The attack rate is defined as the percentage of inoculated participants with at least two consecutive positive swabs as determined by qCulture within the timespan of two consecutive days

    Time frame: 9 days from day 2 to day 10

  4. Time to Start of Viral Shedding (qPCR) From Virus Inoculation

    The Time to Start of Viral Shedding (qPCR) is calculated as (datetime of first of two positive swabs (qPCR) within 2 consecutive days - challenge datetime)/(60\*60)

    Time frame: 9 days from day 2 to day 10

  5. Time to Start of Viral Shedding (qCulture) From Virus Inoculation

    Time to Start of Viral Shedding (qCulture) is calculated as (datetime of first of two positive swabs (qCulture) within 2 consecutive days - challenge datetime)/(60\*60)

    Time frame: 9 days from day 2 to day 10

  6. Peak Viral Shedding (qPCR) After the Virus Inoculation

    This is measured by the highest viral load concentration by qPCR

    Time frame: 9 days from Day 2 to Day 10

  7. Peak Viral Shedding (qCulture) After Virus Inoculation

    This is measured by the highest viral load concentration by qCulture.

    Time frame: 9 days from day 2 to day 10

  8. Time to Peak of Viral Shedding (qPCR) From the Viral Inoculation

    This is calculated as (datetime of highest viral load concentration (qPCR) - challenge datetime)/(60\*60)

    Time frame: 9 days from day 2 to day 10

  9. Time to Peak of Viral Shedding (qCulture) From the Viral Inoculation

    This is calculated as (datetime of highest viral load concentration (qCulture) - challenge datetime)/(60\*60)

    Time frame: 9 days from day 2 to day 10

  10. Duration of Viral Shedding (qPCR) After the Virus Inoculation

    It is calculated as (datetime of first negative swab (qPCR) following the last positive swab (qPCR) - datetime of first positive of two positive swabs (qPCR) within 2 consecutive days)/(60\*60)

    Time frame: 9 days from day2 to day10

  11. Duration of Viral Shedding (qCulture) After the Virus Inoculation

    It is calculated as (datetime of first negative swab (qCulture) following the last positive swab (qCulture) - datetime of first positive of two positive swabs (qCulture) within 2 consecutive days)/(60\*60)

    Time frame: 9 days from day 2 to day 10

  12. Total Area Under the Curve (AUC) of Self-reported Influenza Total Symptom Score (SSC AUC)

    Total symptom scores were compared for MVA-NP+M1 vs. Placebo from Day1 to Day11 post-challenge as AUC of composite score. Symptoms were collected twice a day (lymphadenopathy once a day) on a Symptom Score Card(SSC). SSC recorded scores for each 16 general (gastrointestinal/body systemic) and 12 local (upper/lower respiratory tract) symptoms, on the scale per timepoint (for example Day2,AM). Participants rated the severity of symptoms, higher scores indicating a more severe symptom. The scores ranged from 0 to 3 (0:symptom free, 1:mild, 2:moderate, 3:severe).The SSC also contained the question whether the subject felt well to go to work "today" (yes/no). The Overall SSC score was calculated, as the Arithmetic Mean of the Scores collected across all 28 items on the card per Timepoint and ranged from 0 to maximum 3. The SSC AUC \[0-11 days\] was derived based on the Overall SSC score against time (\*hour), using the linear trapezoidal rule and it ranged from 0 to 110 Score\*hour.

    Time frame: 11 days from Day 1 to Day 11

  13. Total Days of Fever

    Total days of fever for MVA-NP+M1 vs. Placebo

    Time frame: 11 days from Day 1 to Day 11

  14. Average Total Mucus Production

    Total mucus weight of used tissue (regardless of take rate) for MVA-NP+M1 vs. Placebo. Total mucus production was only be calculated in case all tissues were returned (sum of clean and used tissues returned should be 20 tissues for each bag).

    Time frame: 11 days from Day 1 to Day 11

  15. T Cell Responses as Defined by ELISpot Assay in Relation to the Primary Endpoint, Symptom Scores and Influenza Incidence

    T Cell Response was assessed for IFN gamma and granzyme B, on the peripheral blood mononuclear cell using a double-colour enzymatic ELISpot assay. For each of them, three stimulation antigens were assessed: nucleoprotein NP, matrix1 M1 and a negative control, dimethyl sulfoxide (DMSO). The number of spot-forming T cell colonies per well (i.e. 200,000 cells) +/- standard deviation for the total response to NP+M1 is reported. The endpoint was recorded as the mean spot-forming units per million peripheral blood mononuclear cells in the peptide-stimulated wells minus the mean DMSO control wells for the sample. T cell responses over time (sampling timepoints) were then assessed in relation to the primary endpoint, symptom scores, and influenza incidence.

    Time frame: 3 months (day 0, day 8 and day 28 of the vaccination period and day -1 and day 28 of the challenge period)

  16. Number of Participants With MVA-NP+M1 Vaccination Related Adverse Events and Symptoms, Measured by Self-reported Symptoms

    Occurrence of solicited local and systemic reactogenicity signs and symptoms for 7 days following vaccination; self-reported symptoms recorded using paper diaries

    Time frame: 7 days following vaccination

  17. Number of Participants With H3N2 Challenge Related Adverse Events and Symptoms, Measured by Self-reported Symptoms

    Occurrence of solicited local and systemic reactogenicity signs and symptoms; self-reported symptoms recorded using questionnaires and adverse event monitoring

    Time frame: 17 days following vaccination

Other outcomes

  1. Severity of Individual Symptoms for MVA-NP+M1 vs. Placebo

    Severity of individual self-reported symptoms for MVA-NP+M1 vs. Placebo

    Time frame: 11 days

  2. Total Symptom Score Time to Start, Time to Peak and Duration

    Time to start; time to peak and duration of total self-reported symptom score, regardless of take rate Influenza Symptom Score Card of FLU010 - Solicited symptoms for generalized, and upper and lower respiratory tract symptoms scored by severity (0: absent, 1: mild, 2: moderate, or 3: severe).

    Time frame: 11 days

  3. Correlation of T Cell Phenotypes With Illness Outcomes

    Correlation of antigen specific T Cell phenotypes with illness outcomes

    Time frame: 3 months

  4. Vaccination Effect on Antibody Responses by ELISpot and ICS Assays

    Antibody responses of MVA-NP+M1 vs Placebo following influenza challenge measured by ELISpot and Intracellular Cytokine Staining (ICS)

    Time frame: 3 months

07

Results

Posted Mar 18, 2021

Participant flow

The study was conducted at the SGS Clinical Pharmacology Unit in Antwerp, Belgium.

Participant flow — Overall Study
MilestoneMVA-NP+M1 & H3N2 Challenge VirusSaline Placebo & H3N2 Challenge Virus
Started8758
Completed7146
Not completed1612
Withdrew: Physician decision42
Withdrew: Challenge criteria not met / sponsor decision97
Withdrew: Pregnancy10
Withdrew: Adverse event01
Withdrew: Withdrawal by subject12
Withdrew: Lost to follow-up10

Outcome measures

PrimaryDegree of Nasopharyngeal Viral Shedding as Determined by Quantitative Polymerase Chain Reaction qPCR

Measure of nasopharyngeal viral shedding during challenge; recorded as viral area under curve (vAUC) as determined by quantitative real time polymerase chain reaction (qRT-PCR). vAUC is calculated by plotting the log viral particles number/ml for each time point against time and is using the trapezoidal rule.

Time frame:
Throughout 9 days (Day2, Day3, Day4, Day5, Day6, Day7, Day8, Day9, Day10) after viral Inoculation (Day1) of the challenge phase. Nasal swabs taken twice a day (b.i.d) at least 8 hours apart.
Reported as:
Least squares mean · hour*Log10 Viral Particles/ ml
Degree of Nasopharyngeal Viral Shedding as Determined by Quantitative Polymerase Chain Reaction qPCR
hour*Log10 Viral Particles/ mlMVA-NP+M1 (ITT)Placebo (ITT)MVA-NP+M1 (PP)Placebo (PP)MVA-NP+M1 (Challenge)Placebo (Challenge)
Degree of Nasopharyngeal Viral Shedding as Determined by Quantitative Polymerase Chain Reaction qPCR649.7 (552.7 to 746.7)726.1 (604.0 to 848.2)646.5 (548.3 to 744.7)726.1 (604.0 to 848.2)649.7 (552.7 to 746.7)726.1 (604.0 to 848.2)
Statistical analysis
  • MVA-NP+M1 (ITT) vs Placebo (ITT) · Wilcoxon (Mann-Whitney) · p = 0.1711
  • MVA-NP+M1 (PP) vs Placebo (PP) · Wilcoxon (Mann-Whitney) · p = 0.1654
  • MVA-NP+M1 (Challenge) vs Placebo (Challenge) · Wilcoxon (Mann-Whitney) · p = 0.1711
SecondaryNumber and Percentage of Virologically Confirmed Influenza-Like Illness

Incidence (frequency tabulation) of laboratory-confirmed influenza-like illness compared between vaccine and placebo arms Virologically confirmed influenza-like illness (ILI) is defined as having respiratory or flu-like symptom occurring on two consecutive days, along with a positive qPCR or qCulture result.

Time frame:
9 days from day 2 to day 10
Reported as:
Count of participants · Participants
Number and Percentage of Virologically Confirmed Influenza-Like Illness
ParticipantsMVA-NP+M1 (ITT)Placebo (ITT)
Virologically confirmed Influenza-like Illness4329
No Virologically Confirmed Influenza-like Illness2818
Statistical analysis
  • MVA-NP+M1 (ITT) vs Placebo (ITT) · Fisher Exact · p = 1.000
SecondaryPercentage of Participants With Attack Rate of Challenge Agent (qRT-PCR)

The attack rate is defined as the percentage of inoculated participants with at least two consecutive positive swabs as determined by qRT-PCR within the timespan of two consecutive days

Time frame:
9 days from day 2 to day 10
Reported as:
Number · percentage of participants
Percentage of Participants With Attack Rate of Challenge Agent (qRT-PCR)
percentage of participantsMVA-NP+M1 (ITT)Placebo (ITT)
qPCR-confirmed influenza90.1 (80.7 to 95.9)97.9 (88.7 to 99.9)
No qPCR influenza9.9 (4.1 to 19.3)2.1 (0.1 to 11.3)
Statistical analysis
  • MVA-NP+M1 (ITT) vs Placebo (ITT) · Fisher Exact · p = 0.143
SecondaryPercentage of Participants With Quantitative Culture Attack Rate of Challenge Agent (qCulture)

The attack rate is defined as the percentage of inoculated participants with at least two consecutive positive swabs as determined by qCulture within the timespan of two consecutive days

Time frame:
9 days from day 2 to day 10
Reported as:
Number · percentage
Percentage of Participants With Quantitative Culture Attack Rate of Challenge Agent (qCulture)
percentageMVA-NP+M1 (ITT)Placebo (ITT)
qCulture confirmed influenza77.5 (66.0 to 86.5)85.1 (71.7 to 93.8)
No qCulture-confirmed influenza22.5 (13.5 to 34.0)14.9 (6.2 to 28.3)
Statistical analysis
  • MVA-NP+M1 (ITT) vs Placebo (ITT) · Fisher Exact · p = 0.3504
SecondaryTime to Start of Viral Shedding (qPCR) From Virus Inoculation

The Time to Start of Viral Shedding (qPCR) is calculated as (datetime of first of two positive swabs (qPCR) within 2 consecutive days - challenge datetime)/(60\*60)

Time frame:
9 days from day 2 to day 10
Reported as:
Median · hours
Time to Start of Viral Shedding (qPCR) From Virus Inoculation
hoursMVA-NP+M1 (ITT)Placebo (ITT)
Time to Start of Viral Shedding (qPCR) From Virus Inoculation24.40 (24.30 to 24.50)24.30 (24.20 to 24.50)
Statistical analysis
  • MVA-NP+M1 (ITT) vs Placebo (ITT) · Log Rank · p = 0.5558
SecondaryTime to Start of Viral Shedding (qCulture) From Virus Inoculation

Time to Start of Viral Shedding (qCulture) is calculated as (datetime of first of two positive swabs (qCulture) within 2 consecutive days - challenge datetime)/(60\*60)

Time frame:
9 days from day 2 to day 10
Reported as:
Median · hours
Time to Start of Viral Shedding (qCulture) From Virus Inoculation
hoursMVA-NP+M1 (ITT)Placebo (ITT)
Time to Start of Viral Shedding (qCulture) From Virus Inoculation35.9 (35.60 to 48.00)47.6 (24.70 to 48.50)
Statistical analysis
  • MVA-NP+M1 (ITT) vs Placebo (ITT) · Log Rank · p = 0.6534
SecondaryPeak Viral Shedding (qPCR) After the Virus Inoculation

This is measured by the highest viral load concentration by qPCR

Time frame:
9 days from Day 2 to Day 10
Reported as:
Mean · Log10 Viral Particles/ ml
Peak Viral Shedding (qPCR) After the Virus Inoculation
Log10 Viral Particles/ mlMVA-NP+M1 (ITT) Successful AttackPlacebo (ITT) Successful Attack
Peak Viral Shedding (qPCR) After the Virus Inoculation5.876 (5.430 to 6.322)6.054 (5.521 to 6.587)
Statistical analysis
  • MVA-NP+M1 (ITT) Successful Attack vs Placebo (ITT) Successful Attack · Wilcoxon (Mann-Whitney) · p = 0.5485
SecondaryPeak Viral Shedding (qCulture) After Virus Inoculation

This is measured by the highest viral load concentration by qCulture.

Time frame:
9 days from day 2 to day 10
Reported as:
Mean · Log10 Viral Particles/ ml
Peak Viral Shedding (qCulture) After Virus Inoculation
Log10 Viral Particles/ mlMVA-NP+M1 (ITT) Successful AttackPlacebo (ITT) Successful Attack
Peak Viral Shedding (qCulture) After Virus Inoculation4.073 (3.683 to 4.463)4.069 (3.442 to 4.695)
Statistical analysis
  • MVA-NP+M1 (ITT) Successful Attack vs Placebo (ITT) Successful Attack · Wilcoxon (Mann-Whitney) · p = 0.6753
SecondaryTime to Peak of Viral Shedding (qPCR) From the Viral Inoculation

This is calculated as (datetime of highest viral load concentration (qPCR) - challenge datetime)/(60\*60)

Time frame:
9 days from day 2 to day 10
Reported as:
Median · hours
Time to Peak of Viral Shedding (qPCR) From the Viral Inoculation
hoursMVA-NP+M1 (ITT)Placebo (ITT)
Time to Peak of Viral Shedding (qPCR) From the Viral Inoculation72.20 (60.00 to 96.00)107.90 (72.20 to 119.80)
Statistical analysis
  • MVA-NP+M1 (ITT) vs Placebo (ITT) · Log Rank · p = 0.711
SecondaryTime to Peak of Viral Shedding (qCulture) From the Viral Inoculation

This is calculated as (datetime of highest viral load concentration (qCulture) - challenge datetime)/(60\*60)

Time frame:
9 days from day 2 to day 10
Reported as:
Median · hours
Time to Peak of Viral Shedding (qCulture) From the Viral Inoculation
hoursMVA-NP+M1 (ITT)Placebo (ITT)
Time to Peak of Viral Shedding (qCulture) From the Viral Inoculation83.40 (60.10 to 96.30)83.80 (60.10 to 96.40)
Statistical analysis
  • MVA-NP+M1 (ITT) vs Placebo (ITT) · Log Rank · p = 0.4689
SecondaryDuration of Viral Shedding (qPCR) After the Virus Inoculation

It is calculated as (datetime of first negative swab (qPCR) following the last positive swab (qPCR) - datetime of first positive of two positive swabs (qPCR) within 2 consecutive days)/(60\*60)

Time frame:
9 days from day2 to day10
Reported as:
Mean · hours
Duration of Viral Shedding (qPCR) After the Virus Inoculation
hoursMVA-NP+M1 (ITT) Successful AttackPlacebo (ITT) Successful Attack
Duration of Viral Shedding (qPCR) After the Virus Inoculation170.80 (157.08 to 184.52)172.47 (156.99 to 187.94)
SecondaryDuration of Viral Shedding (qCulture) After the Virus Inoculation

It is calculated as (datetime of first negative swab (qCulture) following the last positive swab (qCulture) - datetime of first positive of two positive swabs (qCulture) within 2 consecutive days)/(60\*60)

Time frame:
9 days from day 2 to day 10
Reported as:
Mean · hours
Duration of Viral Shedding (qCulture) After the Virus Inoculation
hoursMVA-NP+M1 (ITT) Successful AttackPlacebo (ITT) Successful Attack
Duration of Viral Shedding (qCulture) After the Virus Inoculation118.19 (105.07 to 131.31)121.78 (106.33 to 137.23)
SecondaryTotal Area Under the Curve (AUC) of Self-reported Influenza Total Symptom Score (SSC AUC)

Total symptom scores were compared for MVA-NP+M1 vs. Placebo from Day1 to Day11 post-challenge as AUC of composite score. Symptoms were collected twice a day (lymphadenopathy once a day) on a Symptom Score Card(SSC). SSC recorded scores for each 16 general (gastrointestinal/body systemic) and 12 local (upper/lower respiratory tract) symptoms, on the scale per timepoint (for example Day2,AM). Participants rated the severity of symptoms, higher scores indicating a more severe symptom. The scores ranged from 0 to 3 (0:symptom free, 1:mild, 2:moderate, 3:severe).The SSC also contained the question whether the subject felt well to go to work "today" (yes/no). The Overall SSC score was calculated, as the Arithmetic Mean of the Scores collected across all 28 items on the card per Timepoint and ranged from 0 to maximum 3. The SSC AUC \[0-11 days\] was derived based on the Overall SSC score against time (\*hour), using the linear trapezoidal rule and it ranged from 0 to 110 Score\*hour.

Time frame:
11 days from Day 1 to Day 11
Reported as:
Geometric mean · Composite symptom score on scale*hour
Total Area Under the Curve (AUC) of Self-reported Influenza Total Symptom Score (SSC AUC)
Composite symptom score on scale*hourMVA-NP+M1 (ITT)Placebo (ITT)
Total Area Under the Curve (AUC) of Self-reported Influenza Total Symptom Score (SSC AUC)16.709 (11.568 to 21.850)20.432 (13.753 to 27.112)
Statistical analysis
  • MVA-NP+M1 (ITT) vs Placebo (ITT) · Wilcoxon (Mann-Whitney) · p = 0.5001
SecondaryTotal Days of Fever

Total days of fever for MVA-NP+M1 vs. Placebo

Time frame:
11 days from Day 1 to Day 11
Reported as:
Mean · days
Total Days of Fever
daysMVA-NP+M1 (ITT)Placebo (ITT)
Total Days of Fever0.0 (0.0 to 0.1)0.0 (0.0 to 0.1)
Statistical analysis
  • MVA-NP+M1 (ITT) vs Placebo (ITT) · zero-inflated poisson model · p = 0.6799
SecondaryAverage Total Mucus Production

Total mucus weight of used tissue (regardless of take rate) for MVA-NP+M1 vs. Placebo. Total mucus production was only be calculated in case all tissues were returned (sum of clean and used tissues returned should be 20 tissues for each bag).

Time frame:
11 days from Day 1 to Day 11
Reported as:
Mean · grams
Average Total Mucus Production
gramsMVA-NP+M1 (ITT)Placebo (ITT)
Average Total Mucus Production31.09 (16.23 to 45.85)38.21 (16.78 to 59.63)
Statistical analysis
  • MVA-NP+M1 (ITT) vs Placebo (ITT) · Wilcoxon (Mann-Whitney) · p = 0.5911
SecondaryT Cell Responses as Defined by ELISpot Assay in Relation to the Primary Endpoint, Symptom Scores and Influenza Incidence

T Cell Response was assessed for IFN gamma and granzyme B, on the peripheral blood mononuclear cell using a double-colour enzymatic ELISpot assay. For each of them, three stimulation antigens were assessed: nucleoprotein NP, matrix1 M1 and a negative control, dimethyl sulfoxide (DMSO). The number of spot-forming T cell colonies per well (i.e. 200,000 cells) +/- standard deviation for the total response to NP+M1 is reported. The endpoint was recorded as the mean spot-forming units per million peripheral blood mononuclear cells in the peptide-stimulated wells minus the mean DMSO control wells for the sample. T cell responses over time (sampling timepoints) were then assessed in relation to the primary endpoint, symptom scores, and influenza incidence.

Time frame:
3 months (day 0, day 8 and day 28 of the vaccination period and day -1 and day 28 of the challenge period)
Reported as:
Mean · Spot-forming units per million
T Cell Responses as Defined by ELISpot Assay in Relation to the Primary Endpoint, Symptom Scores and Influenza Incidence
Spot-forming units per millionMVA-NP+M1 (ITT)Placebo (ITT)
Baseline (Vaccination)230 ± 265167 ± 157
Day 8 (from Vaccination)645 ± 634170 ± 144
Day 28 (from Vaccination)566 ± 551163 ± 160
Day 0 Challenge Period460 ± 471159 ± 132
Day 28 Challenge Period561 ± 483329 ± 220
SecondaryNumber of Participants With MVA-NP+M1 Vaccination Related Adverse Events and Symptoms, Measured by Self-reported Symptoms

Occurrence of solicited local and systemic reactogenicity signs and symptoms for 7 days following vaccination; self-reported symptoms recorded using paper diaries

Time frame:
7 days following vaccination
Reported as:
Count of participants · Participants
Number of Participants With MVA-NP+M1 Vaccination Related Adverse Events and Symptoms, Measured by Self-reported Symptoms
ParticipantsMVA-NP+M1Saline Placebo
TEAE3618
Solicited symptom8424
TEAE or solicited symptom8534
Local solicited symptom808
Local Grade 3 solicited symptom20
Systemic solicited symptom7220
Systemic Grade 3 solicited symptom20
TEAE of special interest00
Serious TEAE10
Non-serious TEAE3618
Grade ≥3 TEAE10
Grade ≥3 TE laboratory toxicity20
Fatal TEAE00
TEAE related to treatment104
Serious TEAE related to treatment10
Grade ≥3 TEAE related to treatment10
TEAE for which the study was discontinued00
SecondaryNumber of Participants With H3N2 Challenge Related Adverse Events and Symptoms, Measured by Self-reported Symptoms

Occurrence of solicited local and systemic reactogenicity signs and symptoms; self-reported symptoms recorded using questionnaires and adverse event monitoring

Time frame:
17 days following vaccination
Reported as:
Count of participants · Participants
Number of Participants With H3N2 Challenge Related Adverse Events and Symptoms, Measured by Self-reported Symptoms
ParticipantsMVA-NP+M1 (Challenge)Placebo (Challenge)
TEAE3021
Solicited symptom6240
TEAE or solicited symptom6542
Local solicited symptom5939
Local Grade 3 solicited symptom00
Systemic solicited symptom4532
Systemic Grade 3 solicited symptom00
TEAE of special interest00
Serious TEAE01
Non-serious TEAE3020
Grade ≥3 TEAE02
Grade ≥3 TE laboratory toxicity72
Fatal TEAE00
TEAE related to challenge75
Serious TEAE related to challenge00
Grade ≥3 TEAE related to challenge00
TEAE for which the study was discontinued01
Other pre-specifiedSeverity of Individual Symptoms for MVA-NP+M1 vs. Placebo

Severity of individual self-reported symptoms for MVA-NP+M1 vs. Placebo

Time frame:
11 days

Results for this outcome have not been posted.

Other pre-specifiedTotal Symptom Score Time to Start, Time to Peak and Duration

Time to start; time to peak and duration of total self-reported symptom score, regardless of take rate Influenza Symptom Score Card of FLU010 - Solicited symptoms for generalized, and upper and lower respiratory tract symptoms scored by severity (0: absent, 1: mild, 2: moderate, or 3: severe).

Time frame:
11 days

Results for this outcome have not been posted.

Other pre-specifiedCorrelation of T Cell Phenotypes With Illness Outcomes

Correlation of antigen specific T Cell phenotypes with illness outcomes

Time frame:
3 months

Results for this outcome have not been posted.

Other pre-specifiedVaccination Effect on Antibody Responses by ELISpot and ICS Assays

Antibody responses of MVA-NP+M1 vs Placebo following influenza challenge measured by ELISpot and Intracellular Cytokine Staining (ICS)

Time frame:
3 months

Results for this outcome have not been posted.

Adverse events

Collected over Any time during the study from the first administration of any study drug until the last study-related activity (the outpatient visit at 27 days ±3 days following the challenge or 6 months following vaccination ±14 days, whichever is longer). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MVA-NP+M1 (Vaccination Phase)0/87 (0%)1/87 (1.1%)36/87 (41.4%)
Saline Placebo (Vaccination Phase)0/58 (0%)0/58 (0%)18/58 (31%)
MVA-NP+M1 (Challenge Phase)0/71 (0%)0/71 (0%)30/71 (42.3%)
Saline Placebo (Challenge Phase)0/47 (0%)1/47 (2.1%)21/47 (44.7%)
Most frequent serious events
Most frequent serious events
EventMVA-NP+M1 (Vaccination Phase)Saline Placebo (Vaccination Phase)MVA-NP+M1 (Challenge Phase)Saline Placebo (Challenge Phase)
Acute PsychosisPsychiatric disorders0/870/580/711/47
Foetal deathPregnancy, puerperium and perinatal conditions1/870/580/710/47
Most frequent other events
Showing 10 of 54
Most frequent other events
EventMVA-NP+M1 (Vaccination Phase)Saline Placebo (Vaccination Phase)MVA-NP+M1 (Challenge Phase)Saline Placebo (Challenge Phase)
Back PainMusculoskeletal and connective tissue disorders3/870/584/716/47
NasopharyngitisInfections and infestations6/874/580/710/47
DiarrhoeaGastrointestinal disorders5/873/583/710/47
HeadacheNervous system disorders5/872/582/711/47
Abdominal PainGastrointestinal disorders1/870/580/712/47
Skin IrritationSkin and subcutaneous tissue disorders2/871/583/711/47
GastroenteritisInfections and infestations0/872/580/710/47
Throat IrritationRespiratory, thoracic and mediastinal disorders3/872/580/710/47
EpistaxisRespiratory, thoracic and mediastinal disorders3/870/582/710/47
UrticariaSkin and subcutaneous tissue disorders3/871/582/710/47

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)MVA-NP+M1 & H3N2 Challenge VirusSaline Placebo & H3N2 Challenge VirusTotal
<=18 years000
Between 18 and 65 years8758145
>=65 years000
Age, Continuous
Age, Continuous(years)MVA-NP+M1 & H3N2 Challenge VirusSaline Placebo & H3N2 Challenge VirusTotal
Median43.00 (18.5 to 55.9)41.25 (19.9 to 55.7)42.50 (18.5 to 55.9)
Sex: Female, Male
Sex: Female, Male(Participants)MVA-NP+M1 & H3N2 Challenge VirusSaline Placebo & H3N2 Challenge VirusTotal
Female473178
Male402767
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MVA-NP+M1 & H3N2 Challenge VirusSaline Placebo & H3N2 Challenge VirusTotal
Asian202
Black or African American404
Middle Eastern011
White8157138
Region of Enrollment
Region of Enrollment(participants)MVA-NP+M1 & H3N2 Challenge VirusSaline Placebo & H3N2 Challenge VirusTotal
Belgium8758145
Smoking Status
Smoking Status(Participants)MVA-NP+M1 & H3N2 Challenge VirusSaline Placebo & H3N2 Challenge VirusTotal
Ex-smoker271845
Non-smoker6040100
Height
Height(cm)MVA-NP+M1 & H3N2 Challenge VirusSaline Placebo & H3N2 Challenge VirusTotal
Median172.40 (153.2 to 193.3)172.30 (151.8 to 191.7)172.40 (151.8 to 193.3)
Weight
Weight(kg)MVA-NP+M1 & H3N2 Challenge VirusSaline Placebo & H3N2 Challenge VirusTotal
Median72.9 (53.2 to 118.8)75.15 (54.6 to 105.6)73.60 (53.2 to 118.8)

1 further baseline measures are reported on the registry.

08

Study locations

1 site
  • SGS Life Sciences, Clinical Pharmacology Unit (CPU)
    Antwerp, 2060, Belgium
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Dec 2019, 6 months.

Results were first posted in Mar 2021, 1 year 3 months after primary completion.

Of 86 industry-sponsored phase 2 interventional studies under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 6 months is below that.

Counting every sponsor, half of 122 studies reached it within 10 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2019
First posted
Mar 20, 2019
StartActual
Jun 3, 2019
Primary completionActual
Dec 16, 2019
CompletionActual
Apr 17, 2020
Results first posted
Mar 18, 2021
Last update
Mar 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03883113
Lead sponsor
Barinthus Biotherapeutics
Responsible party
Sponsor
First posted
Mar 20, 2019
Start date
Jun 3, 2019
Primary completion
Dec 16, 2019
Completion
Apr 17, 2020
Results posted
Mar 18, 2021
Last update
Mar 18, 2021

Study contacts

Robin Rogiers, MD
principal investigator · SGS S.A.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MVA-NP+M1

Start the discussion